Ke Wang1,2, Leila R Zelnick3,2, Andrew N Hoofnagle3,2,4, Tomas Vaisar3, Clark M Henderson4, Peter B Imrey5,6, Cassianne Robinson-Cohen7, Ian H de Boer3,2, Yan-Ting Shiu8, Jonathan Himmelfarb3,2, Gerald J Beck5,6, Bryan Kestenbaum. 1. Departments of Medicine and kewang@uw.edu. 2. Kidney Research Institute, University of Washington, Seattle, Washington. 3. Departments of Medicine and. 4. Laboratory Medicine and. 5. Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. 6. Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. 7. Department of Medicine, Vanderbilt University, Nashville, Tennessee; and. 8. Division of Nephrology and Hypertension, University of Utah School of Medicine, Salt Lake City, Utah.
Abstract
BACKGROUND AND OBJECTIVES: HDL particles obtained from patients on chronic hemodialysis exhibit lower cholesterol efflux capacity and are enriched in inflammatory proteins compared with those in healthy individuals. Observed alterations in HDL proteins could be due to effects of CKD, but also may be influenced by the hemodialysis procedure, which stimulates proinflammatory and prothrombotic pathways. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We compared HDL-associated proteins in 143 participants who initiated hemodialysis within the previous year with those of 110 participants with advanced CKD from the Hemodialysis Fistula Maturation Study. We quantified concentrations of 38 HDL-associated proteins relative to total HDL protein using targeted mass spectrometry assays that included a stable isotope-labeled internal standard. We used linear regression to compare the relative abundances of HDL-associated proteins after adjustment and required a false discovery rate q value ≤10% to control for multiple testing. We further assessed the association between hemodialysis initiation and cholesterol efflux capacity in a subset of 80 participants. RESULTS: After adjustment for demographics, comorbidities, and other clinical characteristics, eight HDL-associated proteins met the prespecified false discovery threshold for association. Recent hemodialysis initiation was associated with higher HDL-associated concentrations of serum amyloid A1, A2, and A4; hemoglobin-β; haptoglobin-related protein; cholesterylester transfer protein; phospholipid transfer protein; and apo E. The trend for participants recently initiating hemodialysis for lower cholesterol efflux capacity compared with individuals with advanced CKD did not reach statistical significance. CONCLUSIONS: Compared with advanced CKD, hemodialysis initiation within the previous year is associated with higher concentrations of eight HDL proteins related to inflammation and lipid metabolism. Identified associations differ from those recently observed for nondialysis-requiring CKD. Hemodialysis initiation may further impair cholesterol efflux capacity. Further work is needed to clarify the clinical significance of the identified proteins with respect to cardiovascular risk. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_07_25_CJASNPodcast_18_8_W.mp3.
BACKGROUND AND OBJECTIVES: HDL particles obtained from patients on chronic hemodialysis exhibit lower cholesterol efflux capacity and are enriched in inflammatory proteins compared with those in healthy individuals. Observed alterations in HDL proteins could be due to effects of CKD, but also may be influenced by the hemodialysis procedure, which stimulates proinflammatory and prothrombotic pathways. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We compared HDL-associated proteins in 143 participants who initiated hemodialysis within the previous year with those of 110 participants with advanced CKD from the Hemodialysis Fistula Maturation Study. We quantified concentrations of 38 HDL-associated proteins relative to total HDL protein using targeted mass spectrometry assays that included a stable isotope-labeled internal standard. We used linear regression to compare the relative abundances of HDL-associated proteins after adjustment and required a false discovery rate q value ≤10% to control for multiple testing. We further assessed the association between hemodialysis initiation and cholesterol efflux capacity in a subset of 80 participants. RESULTS: After adjustment for demographics, comorbidities, and other clinical characteristics, eight HDL-associated proteins met the prespecified false discovery threshold for association. Recent hemodialysis initiation was associated with higher HDL-associated concentrations of serum amyloid A1, A2, and A4; hemoglobin-β; haptoglobin-related protein; cholesterylester transfer protein; phospholipid transfer protein; and apo E. The trend for participants recently initiating hemodialysis for lower cholesterol efflux capacity compared with individuals with advanced CKD did not reach statistical significance. CONCLUSIONS: Compared with advanced CKD, hemodialysis initiation within the previous year is associated with higher concentrations of eight HDL proteins related to inflammation and lipid metabolism. Identified associations differ from those recently observed for nondialysis-requiring CKD. Hemodialysis initiation may further impair cholesterol efflux capacity. Further work is needed to clarify the clinical significance of the identified proteins with respect to cardiovascular risk. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_07_25_CJASNPodcast_18_8_W.mp3.
Authors: Stephen Zewinger; Thimoteus Speer; Marcus E Kleber; Hubert Scharnagl; Rainer Woitas; Philipp M Lepper; Karolin Pfahler; Sarah Seiler; Gunnar H Heine; Winfried März; Günther Silbernagel; Danilo Fliser Journal: J Am Soc Nephrol Date: 2014-03-07 Impact factor: 10.121
Authors: Angel Baldán; Liming Pei; Richard Lee; Paul Tarr; Rajendra K Tangirala; Michael M Weinstein; Joy Frank; Andrew C Li; Peter Tontonoz; Peter A Edwards Journal: Arterioscler Thromb Vasc Biol Date: 2006-08-03 Impact factor: 8.311
Authors: Chantal Kopecky; Bernd Genser; Christiane Drechsler; Vera Krane; Christopher C Kaltenecker; Markus Hengstschläger; Winfried März; Christoph Wanner; Marcus D Säemann; Thomas Weichhart Journal: Clin J Am Soc Nephrol Date: 2014-11-25 Impact factor: 8.237
Authors: Nathalie Pamir; Patrick Hutchins; Graziella Ronsein; Tomas Vaisar; Catherine A Reardon; Godfrey S Getz; Aldons J Lusis; Jay W Heinecke Journal: J Lipid Res Date: 2015-12-15 Impact factor: 5.922
Authors: Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay Journal: Int Urol Nephrol Date: 2018-12-05 Impact factor: 2.370
Authors: Monique F M Santana; Aécio L A Lira; Raphael S Pinto; Carlos A Minanni; Amanda R M Silva; Maria I B A C Sawada; Edna R Nakandakare; Maria L C Correa-Giannella; Marcia S Queiroz; Graziella E Ronsein; Marisa Passarelli Journal: Lipids Health Dis Date: 2020-09-14 Impact factor: 3.876